Interlaboratory Reproducibility of Standardized Hemagglutination Inhibition Assays

Bibby, David C.; Savanovic, Michael; Zhang, Jinrong; Torelli, Alessandro; Jeeninga, Rienk E.; Gagnon, Luc; Harris, Shannon L.

doi:10.1128/msphere.00953-21

Cited by 6 publications

(7 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, as this model becomes more commonly employed in laboratories worldwide, there is a pressing need to capture the level of variability and heterogeneity intrinsic to this research. Cross-laboratory exercises have been employed in the past to evaluate the reproducibility of assays employed for influenza virus public health efforts (3)(4)(5)(6)44), but no such exercise has been performed to date evaluating influenza virus transmissibility in the ferret. In this exercise, 11 laboratories independently evaluated the ferret-to-ferret transmissibility of Cal/09 and ruddy turnstone/09 viruses that possess distinct transmission potential in humans.…”

Section: Discussionmentioning

confidence: 99%

“…These characterization efforts are undertaken by laboratories worldwide, employing zoonotic virus strains and experimental protocols that are similar but not uniform, which may lead to variation in the experimental results. To date, limited assessments of interlaboratory variability have been conducted for influenza virus serological assays (3)(4)(5)(6), but not for other in vitro or in vivo assays.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Robustness of the Ferret Model for Influenza Risk Assessment Studies: a Cross-Laboratory Exercise

Belser

Lau

Barclay

et al. 2022

mBio

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Robustness of the Ferret Model for Influenza Risk Assessment Studies: a Cross-Laboratory Exercise

Belser

Lau

Barclay

et al. 2022

mBio

View full text Add to dashboard Cite

show abstract

“…The Ad26.COV2.S vaccine has been subjected to large phase III clinical trials with 60,000 participants (Coughlan, 2020, Bibby et al, 2022. As mentioned earlier, simian adenovirus vectors have been used for SARS-CoV-2 vaccine development to address any potential pre-existing immunity against human adenoviruses in the population (Folegatti et al, 2022).…”

Section: Non-human Adenovirus Vaccinesmentioning

confidence: 99%

An Overview of Adenovirus Vector-based Vaccines against SARS-CoV-2

Zeedan¹,

Abdalhamed²,

Naguib³

et al. 2023

WVJ

View full text Add to dashboard Cite

Adenovirus vectors have been employed to develop a vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for curtailing the Covid-19 pandemic spreading. Many different viral vectors have been mainly targeting the SARS-CoV-2 spike (S) protein as an antigen. Spike (S) protein is comprised of S1 and S2 subunits, in which the receptor-binding domain (RBD) of S1 is responsible for recognizing and engaging with its host cellular receptor protein angiotensin-converting enzyme 2 (ACE2), S2 accounts for membrane fusion of virus and host cell. Chimpanzee adenovirus was also used as a vector vaccine for SARS-CoV-2 (ChAdSARS-CoV-2-S) by intramuscular injection, and intranasal administration has been tested. Adenovirus vector-based vaccines are the most advanced, with several vaccines receiving Emergency Use Authorization (EUA). It was shown that rhesus macaques were protected from SARS-CoV-2 challenge after a month of being vaccinated with ChAd-SARS-CoV-2-S. A single intranasal or two intramuscular ChAd-SARSCoV-2-S vaccines could induce humoral antibodies and T cell responses to protect the upper and lower respiratory tract against SARS-CoV-2. As the effectiveness was demonstrated in non-human primates, ChAd-SARS-CoV-2-Sa potential option for preventing SARS-CoV-2 infection in humans. However, detecting novel more transmissible and pathogenic SARS-CoV-2 variants added concerns about the vaccine efficacy and needs monitoring. Moreover, the cause of recently documented rare cases of vaccine indicated immune thrombotic thrombocytopenia. This review article provided details for the adenovirus vector vaccine for SARS-CoV-2 in humans and tried to provide solutions to the adenovirus vector hemagglutinin issue.

show abstract

“…(4) However, complex N-glycans seem to be essential for contemporary human H3N2 influenza viruses. This analysis is lacking for H1N1 viruses; however, these do still bind erythrocytes, (4,12) indicating a binding capability to N-glycans containing 2 LacNAc repeats terminating in a2-6 linked sialic acid. Studies carried out with glycan arrays have shown that H3 Vic/11 prefers human-type branched N-glycans with at least three LacNAc repeats.…”

Section: Introductionmentioning

confidence: 98%

Revealing the evolution towards complex N-glycan specificities of human H1 influenza A viruses.

Canales

Sastre

Orduña

et al. 2022

Preprint

View full text Add to dashboard Cite

Influenza virus infection remains a threat to human health since viral hemagglutinins are constantly drifting, escaping infec-tion and vaccine-induced antibody responses. During antigenic drift H3 hemagglutinins have evolved to recognize a2,6 sialylated branched N-glycans with long glycan chains with at least three N-acetyllactosamine units (tri-LacNAc). In this work, we combined glycan arrays and tissue binding analyses with NMR experiments to characterize the interaction of a family of H1 variants, including the one responsible for the last pandemic outbreak. We also analyzed one H6 to understand if the preference for tri-LacNAc motifs is a general trend in recent zoonotic human-type receptor binding adapted viruses. In addition, we developed a new NMR approach to perform competition experiments between glycans with similar compositions and different lengths. Pandemic H1 viruses differ from previous seasonal H1 viruses by a strict preference for a minimum of di-LacNAc structural motif that are in turn present on the ferret upper respiratory tract.

show abstract

Interlaboratory Reproducibility of Standardized Hemagglutination Inhibition Assays

Abstract: Licensure of influenza vaccines relies on the hemagglutination inhibition (HI) assay as the primary method to determine quantitative functional antibody titers. The HI assay is also widely used for influenza virus surveillance, characterization, and epidemiology studies.

Cited by 6 publications

References 10 publications

Robustness of the Ferret Model for Influenza Risk Assessment Studies: a Cross-Laboratory Exercise

Robustness of the Ferret Model for Influenza Risk Assessment Studies: a Cross-Laboratory Exercise

An Overview of Adenovirus Vector-based Vaccines against SARS-CoV-2

Revealing the evolution towards complex N-glycan specificities of human H1 influenza A viruses.

Contact Info

Product

Resources

About